Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With Psoriasis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effect of etanercept 50 mg twice weekly
compared to placebo over 12 weeks on the psoriasis area and severity index (PASI) in subjects
with psoriasis. This study will also evaluate the safety and tolerability of etanercept 50 mg
twice weekly; determine the effect of etanercept 50 mg twice weekly on patient reported
outcomes (PRO); and characterize the pharmacokinetics (PK) profile of etanercept 50 mg twice
weekly.